1125 related articles for article (PubMed ID: 17173447)
1. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
[TBL] [Abstract][Full Text] [Related]
2. Chloro half-sandwich osmium(II) complexes: influence of chelated N,N-ligands on hydrolysis, guanine binding, and cytotoxicity.
Peacock AF; Habtemariam A; Moggach SA; Prescimone A; Parsons S; Sadler PJ
Inorg Chem; 2007 May; 46(10):4049-59. PubMed ID: 17441712
[TBL] [Abstract][Full Text] [Related]
3. The contrasting chemistry and cancer cell cytotoxicity of bipyridine and bipyridinediol ruthenium(II) arene complexes.
Bugarcic T; Habtemariam A; Stepankova J; Heringova P; Kasparkova J; Deeth RJ; Johnstone RD; Prescimone A; Parkin A; Parsons S; Brabec V; Sadler PJ
Inorg Chem; 2008 Dec; 47(24):11470-86. PubMed ID: 19007206
[TBL] [Abstract][Full Text] [Related]
4. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity.
Peacock AF; Parsons S; Sadler PJ
J Am Chem Soc; 2007 Mar; 129(11):3348-57. PubMed ID: 17319668
[TBL] [Abstract][Full Text] [Related]
5. Ruthenium(II) arene anticancer complexes with redox-active diamine ligands.
Bugarcic T; Habtemariam A; Deeth RJ; Fabbiani FP; Parsons S; Sadler PJ
Inorg Chem; 2009 Oct; 48(19):9444-53. PubMed ID: 19780621
[TBL] [Abstract][Full Text] [Related]
6. New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.
Hotze AC; Bacac M; Velders AH; Jansen BA; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
J Med Chem; 2003 Apr; 46(9):1743-50. PubMed ID: 12699392
[TBL] [Abstract][Full Text] [Related]
7. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
[TBL] [Abstract][Full Text] [Related]
8. Coordination of 9-ethylguanine to the mixed-ligand compound alpha-[Ru(azpy)(bpy)Cl2] (azpy = 2-phenylazopyridine and bpy = 2,2'-bipyridine). An unprecedented ligand positional shift, correlated to the cytotoxicity of this type of [RuL2Cl2] (with L = azpy or bpy) complex.
Hotze AC; van der Geer EP; Caspers SE; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
Inorg Chem; 2004 Aug; 43(16):4935-43. PubMed ID: 15285670
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.
Habtemariam A; Melchart M; Fernandez R; Parsons S; Oswald ID; Parkin A; Fabbiani FP; Davidson JE; Dawson A; Aird RE; Jodrell DI; Sadler PJ
J Med Chem; 2006 Nov; 49(23):6858-68. PubMed ID: 17154516
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes.
Vock CA; Scolaro C; Phillips AD; Scopelliti R; Sava G; Dyson PJ
J Med Chem; 2006 Sep; 49(18):5552-61. PubMed ID: 16942028
[TBL] [Abstract][Full Text] [Related]
11. Chlorido-, aqua-, 9-ethylguanine- and 9-ethyladenine-adducts of cytotoxic ruthenium arene complexes containing O,O-chelating ligands.
Melchart M; Habtemariam A; Parsons S; Sadler PJ
J Inorg Biochem; 2007 Nov; 101(11-12):1903-12. PubMed ID: 17582501
[TBL] [Abstract][Full Text] [Related]
12. Dichlorobis(2-phenylazopyridine)ruthenium(II) complexes: characterisation, spectroscopic and structural properties of four isomers.
Velders AH; van der Schilden K; Hotze AC; Reedijk J; Kooijman H; Spek AL
Dalton Trans; 2004 Feb; (3):448-55. PubMed ID: 15252553
[TBL] [Abstract][Full Text] [Related]
13. Bipyrimidine ruthenium(II) arene complexes: structure, reactivity and cytotoxicity.
Betanzos-Lara S; Novakova O; Deeth RJ; Pizarro AM; Clarkson GJ; Liskova B; Brabec V; Sadler PJ; Habtemariam A
J Biol Inorg Chem; 2012 Oct; 17(7):1033-51. PubMed ID: 22791215
[TBL] [Abstract][Full Text] [Related]
14. Ferrocenoyl pyridine arene ruthenium complexes with anticancer properties: synthesis, structure, electrochemistry, and cytotoxicity.
Auzias M; Therrien B; Süss-Fink G; Stepnicka P; Ang WH; Dyson PJ
Inorg Chem; 2008 Jan; 47(2):578-83. PubMed ID: 18085776
[TBL] [Abstract][Full Text] [Related]
15. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
[TBL] [Abstract][Full Text] [Related]
16. Use of chelating ligands to tune the reactive site of half-sandwich ruthenium(II)-arene anticancer complexes.
Fernández R; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Chemistry; 2004 Oct; 10(20):5173-9. PubMed ID: 15372674
[TBL] [Abstract][Full Text] [Related]
17. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.
Novakova O; Chen H; Vrana O; Rodger A; Sadler PJ; Brabec V
Biochemistry; 2003 Oct; 42(39):11544-54. PubMed ID: 14516206
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of aquation and anation of ruthenium(II) arene anticancer complexes, acidity and X-ray structures of aqua adducts.
Wang F; Chen H; Parsons S; Oswald ID; Davidson JE; Sadler PJ
Chemistry; 2003 Dec; 9(23):5810-20. PubMed ID: 14673852
[TBL] [Abstract][Full Text] [Related]
19. Organometallic osmium(II) arene anticancer complexes containing picolinate derivatives.
van Rijt SH; Peacock AF; Johnstone RD; Parsons S; Sadler PJ
Inorg Chem; 2009 Feb; 48(4):1753-62. PubMed ID: 19146436
[TBL] [Abstract][Full Text] [Related]
20. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.
Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ
Inorg Chem; 2006 Oct; 45(22):9006-13. PubMed ID: 17054361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]